Want to see TSE:NLH full AI Analyst Report?
Top Page
Nova Leap Health
(NLH)
Select Model
Select Model
Rating:68Neutral
Price Target:
C$0.60
▲(7.14% Upside)
Action:Reiterated
Date:08/17/26
The score is driven primarily by improving (but still inconsistent) financial performance—profitability has returned and leverage is conservative, but margins and cash conversion remain uneven. Technical signals are a meaningful positive with price above key moving averages and positive momentum indicators, partially offset by near-overbought stochastic readings. Valuation is a modest headwind given the P/E level and lack of dividend support in the provided data.
Positive Factors
Conservative leverage
Conservative leverage gives Nova Leap financial flexibility as it funds operations and pursues agency growth. A meaningful equity base relative to assets reduces balance-sheet risk, limits financing pressure, and improves resilience if operating conditions become less favorable.
Negative Factors
Thin net margins
A net margin of about 4% leaves limited room for wage, administrative, insurance, or other operating cost increases. Thin profitability makes earnings more sensitive to modest changes in pricing, caregiver utilization, and overhead, reducing the durability of returns.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative leverage
Conservative leverage gives Nova Leap financial flexibility as it funds operations and pursues agency growth. A meaningful equity base relative to assets reduces balance-sheet risk, limits financing pressure, and improves resilience if operating conditions become less favorable.
Read all positive factors
Nova Leap Health (NLH) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$48.02M
Dividend YieldN/A
Average Volume (3M)23.39K
Price to Earnings (P/E)26.1
Beta (1Y)0.25
Revenue Growth18.35%
EPS Growth1021.05%
CountryCA
Employees541
SectorGeneral
Sector StrengthN/A
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)0.02
Shares Outstanding87,314,255
10 Day Avg. Volume9,872
30 Day Avg. Volume23,389
Financial Highlights & Ratios
PEG Ratio0.81
Price to Book (P/B)0.94
Price to Sales (P/S)0.56
P/FCF Ratio12.58
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Nova Leap Health Business Overview & Revenue Model
Company Description
Nova Leap Health Corp. delivers a comprehensive array of in-home and healthcare-at-home solutions across the United States and Canada. Their offerings encompass specialized dementia support, social companionship, assistance with personal needs, an...
How the Company Makes Money
NLH makes money primarily by delivering home care services through its operating agencies and charging for caregiver time and related service visits. Revenue is generated on an hourly (or visit-based) basis for non-medical home care support such a...
Nova Leap Health Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
74
Positive
Cash Flow
56
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 33.23M | 32.02M | 25.76M | 26.18M | 28.21M | 21.28M |
| Gross Profit | 12.94M | 11.85M | 9.89M | 9.77M | 9.98M | 7.21M |
| EBITDA | 2.71M | 1.97M | 2.50M | 994.47K | 420.35K | 4.76M |
| Net Income | 1.32M | -193.19K | 1.38M | -1.05M | -835.75K | 1.76M |
Balance Sheet | ||||||
| Total Assets | 25.75M | 23.44M | 22.39M | 20.90M | 23.95M | 26.77M |
| Cash, Cash Equivalents and Short-Term Investments | 1.44M | 1.49M | 1.40M | 894.76K | 1.27M | 1.73M |
| Total Debt | 4.45M | 2.93M | 2.53M | 1.40M | 3.97M | 6.20M |
| Total Liabilities | 6.37M | 4.43M | 4.14M | 2.70M | 5.27M | 8.29M |
| Stockholders Equity | 19.39M | 19.01M | 18.25M | 18.20M | 18.68M | 18.48M |
Cash Flow | ||||||
| Free Cash Flow | 1.95M | 1.42M | 1.36M | 2.13M | 949.49K | 2.18M |
| Operating Cash Flow | 1.91M | 1.42M | 1.39M | 2.15M | 1.02M | 2.18M |
| Investing Cash Flow | -2.25M | -1.26M | -1.59M | -23.13K | -56.24K | -7.40M |
| Financing Cash Flow | 388.04K | -86.91K | 729.78K | -2.52M | -1.41M | 4.33M |
Nova Leap Health Technical Analysis
Positive
0.56
Price Trends
0.47
Positive
0.42
Positive
0.37
Positive
Market Momentum
0.02
Positive
55.18
Neutral
47.62
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:NLH, the sentiment is Positive. The current price of 0.56 is above the 20-day moving average (MA) of 0.54, above the 50-day MA of 0.47, and above the 200-day MA of 0.37, indicating a bullish trend. The MACD of 0.02 indicates Positive momentum. The RSI at 55.18 is Neutral, neither overbought nor oversold. The STOCH value of 47.62 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:NLH.
Nova Leap Health Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | C$202.44M | 7.44 | 25.79% | 2.51% | 2.96% | ― | |
73 Outperform | C$2.95B | 23.49 | 36.33% | 1.67% | 31.14% | 34.48% | |
68 Neutral | C$48.02M | 26.09 | 6.95% | ― | 18.35% | 1021.05% | |
62 Neutral | C$248.91M | 8.66 | 45.36% | 2.34% | 2.64% | -56.04% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
54 Neutral | C$2.20B | 38.10 | 6.58% | 4.72% | 16.11% | 31.75% |
* General Sector Average
TSE:NLH
Nova Leap Health
0.55
0.25
83.33%
TSE:CRRX
CareRx
3.19
0.03
1.01%
TSE:EXE
Extendicare
31.01
17.98
138.03%
TSE:SIA
Sienna Senior Living
19.81
2.35
13.45%
TSE:DR
Medical Facilities
15.39
0.88
6.06%
Nova Leap Health Corporate Events
Business Operations and StrategyFinancial DisclosuresM&A Transactions
Nova Leap Health Delivers Record Q2 Results and Accelerates Home Care Expansion
Positive
Aug 7, 2026
Nova Leap Health Corp. reported record financial results for the second quarter of 2026, with revenue rising 17.1% year over year to $9.39 million and trailing twelve-month revenue reaching $33.6 million, the highest in the company’s history...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.